insights_auto
Outlook: 53.8% bullish·7.7% bearish
Go to analysischevron_right
GSK:LON
GSK plc
GBXÂ 1,868.50
arrow_upward
+0.73%(+13.50) 1D
Oct 20, 4:37:14 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
GBXÂ 1,870.00
High
GBXÂ 1,880.00
Low
GBXÂ 1,855.00
Mkt. cap
102.38B
Avg. vol.
6.42M
Volume
5.08M
Dividend
3.64%
Quarterly dividend
GBXÂ 17.00
Ex-dividend date
Aug 13, 2026
P/E ratio
15.83
52-wk high
GBXÂ 2,282.00
52-wk low
GBXÂ 1,592.00
EPS
GBXÂ 1.18
Shares outstanding
4.32B
No. of employees
67K
Open
GBXÂ 1,870.00
High
GBXÂ 1,880.00
Low
GBXÂ 1,855.00
Mkt. cap
102.38B
Avg. vol.
6.42M
Volume
5.08M
Dividend
3.64%
Quarterly dividend
GBXÂ 17.00
Ex-dividend date
Aug 13, 2026
P/E ratio
15.83
52-wk high
GBXÂ 2,282.00
52-wk low
GBXÂ 1,592.00
EPS
GBXÂ 1.18
Shares outstanding
4.32B
No. of employees
67K
News stories
From web sources and news partners
Reuters
·
1 hour ago
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
ad-hoc-news.de
·
8 hours ago
GSK stock: At 17.97 percent below its 52-week high, GSK stock sits
Zacks Investment Research
·
9 hours ago
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com